{"id":"concurrent-pd-1-antibody","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Colitis"}]},"_chembl":{"chemblId":"CHEMBL1474985","moleculeType":"Small molecule","molecularWeight":"476.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 inhibitors work by releasing the 'brakes' on T cell-mediated immunity. Cancer cells often express PD-L1, which binds to PD-1 on T cells and suppresses anti-tumor immune responses. By blocking this interaction, PD-1 antibodies restore T cell activation and proliferation, enabling durable anti-tumor immunity. The term 'concurrent' suggests this agent may be used in combination with other therapies.","oneSentence":"A PD-1 antibody that blocks the PD-1 checkpoint protein on T cells, allowing the immune system to recognize and attack cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:24.343Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not yet defined in phase 3)"}]},"trialDetails":[{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT07469306","phase":"PHASE2","title":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-08-10","conditions":"Locally Advanced Rectal Cancer","enrollment":130},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT07010263","phase":"PHASE3","title":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-13","conditions":"Small Cell Lung Cancer","enrollment":560},{"nctId":"NCT07447570","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-15","conditions":"Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody","enrollment":27},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":"Nasopharangeal Cancer","enrollment":142},{"nctId":"NCT03340129","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2019-08-14","conditions":"Melanoma Stage Iv","enrollment":218},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07373990","phase":"PHASE3","title":"Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-15","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":418},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT06069830","phase":"NA","title":"PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-12-06","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":89},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT02989636","phase":"PHASE1","title":"Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-03-10","conditions":"Chordoma","enrollment":21},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07277764","phase":"PHASE2","title":"Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms","enrollment":23},{"nctId":"NCT07188584","phase":"PHASE3","title":"Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-08-20","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":166},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT07232654","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-11","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":30},{"nctId":"NCT06364384","phase":"PHASE2","title":"Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-04-12","conditions":"Rectal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT04369937","phase":"PHASE2","title":"HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for \"Intermediate Risk\" HPV-16-associated Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-07-06","conditions":"HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma","enrollment":18},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT07154316","phase":"PHASE2","title":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":138},{"nctId":"NCT07110558","phase":"PHASE2","title":"Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-15","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT07090707","phase":"PHASE2","title":"PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-01","conditions":"HNSCC, PD-1, Radiotherapy","enrollment":50},{"nctId":"NCT06579196","phase":"PHASE1, PHASE2","title":"Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-05-12","conditions":"Non-small Cell Lung Cancer","enrollment":45},{"nctId":"NCT07064902","phase":"PHASE2","title":"Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":48},{"nctId":"NCT03984357","phase":"PHASE2","title":"Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-03-16","conditions":"Nasopharyngeal Carcinoma","enrollment":152},{"nctId":"NCT04907370","phase":"PHASE3","title":"PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":532},{"nctId":"NCT05161572","phase":"PHASE2","title":"Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Fudan University","startDate":"2021-09-28","conditions":"Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy","enrollment":6},{"nctId":"NCT07020247","phase":"PHASE3","title":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-19","conditions":"Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy","enrollment":184},{"nctId":"NCT04821765","phase":"PHASE2","title":"Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-10-01","conditions":"Esophagus Cancer, Chemoradiotherapy, Oligometastatic Disease","enrollment":35},{"nctId":"NCT05941481","phase":"PHASE2","title":"Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2023-06-10","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":21},{"nctId":"NCT06749899","phase":"PHASE3","title":"QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2025-05-04","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":580},{"nctId":"NCT06957938","phase":"PHASE3","title":"Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-04-28","conditions":"Laryngeal Carcinoma, Hypopharyngeal Carcinoma","enrollment":168},{"nctId":"NCT04494009","phase":"PHASE2","title":"PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asan Medical Center","startDate":"2020-09-07","conditions":"Esophageal Cancer","enrollment":110},{"nctId":"NCT04776447","phase":"PHASE2","title":"Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-06-16","conditions":"Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT06715501","phase":"NA","title":"Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2024-12-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages","enrollment":20},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT03632941","phase":"PHASE2","title":"A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herbert Lyerly","startDate":"2019-03-01","conditions":"Breast Cancer, HER2+ Breast Cancer","enrollment":8},{"nctId":"NCT05743270","phase":"PHASE2","title":"Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN","status":"WITHDRAWN","sponsor":"Replimune Inc.","startDate":"2024-01-30","conditions":"Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT04709380","phase":"PHASE3","title":"Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT","status":"TERMINATED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-03-02","conditions":"Radiotherapy, Toripalimab, Sorafenib","enrollment":36},{"nctId":"NCT05587374","phase":"PHASE3","title":"Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-08-01","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer","enrollment":490},{"nctId":"NCT03715946","phase":"PHASE2","title":"Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer","status":"COMPLETED","sponsor":"Robert L. Ferris, MD, PhD","startDate":"2018-11-16","conditions":"Carcinoma, Squamous Cell of Head and Neck, Oropharynx Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06751394","phase":"PHASE2","title":"Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-01","conditions":"Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT06725498","phase":"PHASE2","title":"Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2024-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT05060471","phase":"PHASE2","title":"PD-1 Blockade Combined with Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-10-27","conditions":"Anal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer","enrollment":25},{"nctId":"NCT02791334","phase":"PHASE1","title":"A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-06-29","conditions":"Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma","enrollment":164},{"nctId":"NCT06041477","phase":"PHASE3","title":"Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-31","conditions":"Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":540},{"nctId":"NCT04220944","phase":"PHASE1","title":"Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-01-01","conditions":"Hepatic Carcinoma","enrollment":45},{"nctId":"NCT04435197","phase":"PHASE2","title":"Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-08-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":143},{"nctId":"NCT06477523","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-16","conditions":"SCLC, Extensive Stage","enrollment":57},{"nctId":"NCT06462053","phase":"PHASE2","title":"Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Early Low Rectal Cancer","enrollment":134},{"nctId":"NCT05490719","phase":"PHASE2","title":"A Phase II Study of CRT Combined With QL1706 in ESCC Patients","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT06406673","phase":"PHASE2","title":"A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-10-16","conditions":"Extensive Small Cell Lung Cancer","enrollment":70},{"nctId":"NCT05443646","phase":"PHASE2","title":"Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-09-23","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":55},{"nctId":"NCT01928576","phase":"PHASE2","title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-11-06","conditions":"Non-Small Cell Lung Cancer, Epigenetic Therapy","enrollment":143},{"nctId":"NCT04557020","phase":"PHASE3","title":"Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC","status":"UNKNOWN","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2020-12-30","conditions":"Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT06151743","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-01-18","conditions":"Locally Advanced Hypopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT04301557","phase":"PHASE2","title":"PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-07-31","conditions":"DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer","enrollment":25},{"nctId":"NCT06345287","phase":"PHASE2","title":"Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-01","conditions":"Head and Neck Cancer","enrollment":133},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT06170710","phase":"PHASE2","title":"Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-12-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":173},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT06095167","phase":"PHASE3","title":"Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":476},{"nctId":"NCT05777824","phase":"PHASE2","title":"Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-01","conditions":"Head and Neck Cancer","enrollment":84},{"nctId":"NCT06031597","phase":"PHASE3","title":"Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-09-15","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":105},{"nctId":"NCT05511623","phase":"PHASE2","title":"Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2022-09-01","conditions":"Cervical Cancer","enrollment":112},{"nctId":"NCT02858921","phase":"PHASE2","title":"Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma","status":"UNKNOWN","sponsor":"Melanoma Institute Australia","startDate":"2017-11-08","conditions":"Melanoma","enrollment":60},{"nctId":"NCT04156698","phase":"PHASE2","title":"Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2020-05-21","conditions":"Hypopharyngeal Carcinoma, Immunotherapy, Chemotherapy","enrollment":51},{"nctId":"NCT05980715","phase":"PHASE3","title":"PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-01-01","conditions":"HNSCC, Radiotherapy, PD-1","enrollment":324},{"nctId":"NCT02499835","phase":"PHASE1, PHASE2","title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-07-01","conditions":"Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues","enrollment":66},{"nctId":"NCT03925090","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-08","conditions":"Nasopharyngeal Carcinoma","enrollment":150},{"nctId":"NCT05859373","phase":"PHASE1, PHASE2","title":"To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-06","conditions":"Non-small Cell Lung Cancer","enrollment":78},{"nctId":"NCT05213884","phase":"PHASE2","title":"The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-01-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03700476","phase":"PHASE3","title":"Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-12-21","conditions":"Nasopharyngeal Neoplasms","enrollment":425},{"nctId":"NCT05097209","phase":"PHASE2","title":"Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Wei Jiang","startDate":"2022-04-06","conditions":"Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT05707819","phase":"","title":"Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Cancer Hospital of Guangxi Medical University","startDate":"2022-07-30","conditions":"Nasopharyngeal Carcinoma, Sintilimab","enrollment":43},{"nctId":"NCT05628922","phase":"PHASE2","title":"Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-07-02","conditions":"Nasopharyngeal Cancer","enrollment":198},{"nctId":"NCT02434081","phase":"PHASE2","title":"NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-11-25","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":94},{"nctId":"NCT05505461","phase":"PHASE2","title":"Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2023-01","conditions":"Adenocarcinoma of Esophagogastric Junction","enrollment":26},{"nctId":"NCT05265650","phase":"PHASE1, PHASE2","title":"Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2022-06-13","conditions":"Non-Small Cell Lung Cancer Metastatic","enrollment":30},{"nctId":"NCT05424432","phase":"PHASE2","title":"Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-04-29","conditions":"Locally Advanced Esophageal Carcinoma","enrollment":63},{"nctId":"NCT02684461","phase":"PHASE2","title":"Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-09-13","conditions":"Non Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT05374252","phase":"PHASE3","title":"Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-05-07","conditions":"Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma, Anal Canal Cancer","enrollment":102},{"nctId":"NCT05342792","phase":"PHASE3","title":"Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-04-17","conditions":"Nasopharyngeal Carcinoma","enrollment":556},{"nctId":"NCT05341193","phase":"PHASE1, PHASE2","title":"PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-04-30","conditions":"Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT05311566","phase":"PHASE2","title":"PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer","status":"RECRUITING","sponsor":"Lei Li","startDate":"2022-03-27","conditions":"Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1","enrollment":92},{"nctId":"NCT05310305","phase":"","title":"PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer","status":"UNKNOWN","sponsor":"Lei Li","startDate":"2022-03-26","conditions":"Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody, Radiotherapy","enrollment":20},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT05254899","phase":"PHASE2","title":"Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-10-01","conditions":"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer","enrollment":54},{"nctId":"NCT05149170","phase":"PHASE2","title":"Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-10-01","conditions":"Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":30},{"nctId":"NCT04605562","phase":"PHASE2","title":"Umbrella Biomarker-Guided Therapy in NPC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-06","conditions":"Nasopharyngeal Carcinoma","enrollment":206},{"nctId":"NCT04888403","phase":"PHASE2","title":"Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2021-12-31","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT04539600","phase":"PHASE2","title":"Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-11-01","conditions":"Hypopharyngeal Cancer, Immunotherapy, Induction Chemotherapy","enrollment":23},{"nctId":"NCT04376866","phase":"PHASE3","title":"Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Cancer Hospital of Guangxi Medical University","startDate":"2020-06-28","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":74,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Concurrent immunotherapy"],"phase":"phase_3","status":"active","brandName":"Concurrent PD-1 antibody","genericName":"Concurrent PD-1 antibody","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Concurrent PD-1 antibody is not mentioned in the provided facts. However, based on the information given, a related treatment is being studied in combination with Bevacizumab and Lomustine for various conditions, including Glioblastoma, Locally Advanced Rectal Cancer, and Hypopharyngeal Carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}